NCT00142467View on ClinicalTrials.gov

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

June 30, 2011

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Gemcitabine

DRUG

Oxaliplatin

DRUG

Bevacizumab

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Sanofi-Synthelabo

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

Massachusetts General Hospital

OTHER